Thalamocortical functional connectivity and cannabis use in men with childhood attention-deficit/hyperactivity disorder

PLoS One. 2022 Nov 28;17(11):e0278162. doi: 10.1371/journal.pone.0278162. eCollection 2022.

Abstract

Disruptions of the cortico-striato-thalamo-cortical circuit has been implicated in both attention-deficit/hyperactivity disorder and substance use disorder. Given the high prevalence of cannabis use among patients with attention-deficit/hyperactivity disorder, we set out to investigate the relationship between the two in the thalamus. We analyzed resting-state functional magnetic resonance imaging data obtained from the Addiction Connectome Preprocessed Initiative Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder database. Functional connectivity maps were extracted to compare thalamic connectivity among adults who had been diagnosed with attention-deficit/hyperactivity disorder during childhood according to whether or not they used cannabis. The study participants included 18 cannabis users and 15 cannabis non-users with childhood attention-deficit/hyperactivity disorder. Our results revealed that adults with attention-deficit/hyperactivity disorder who used cannabis (n = 18) had significantly decreased functional connectivity between the thalamus and parietal regions, which was particularly prominent in the inferior parietal areas, in comparison with those who did not use cannabis (n = 15). Left thalamic functional connectivity with the inferior parietal and middle frontal areas and right thalamic functional connectivity with the inferior parietal and superior frontal areas were increased in non-users of cannabis with attention-deficit/hyperactivity disorder compared with a local normative comparison group (n = 7). In conclusion, adults with a childhood history of attention-deficit/hyperactivity disorder who do not use cannabis often have relatively stronger thalamoparietal and thalamofrontal connectivity, which may help reduce the risk of cannabis use.

MeSH terms

  • Adult
  • Analgesics
  • Attention Deficit Disorder with Hyperactivity* / diagnostic imaging
  • Cannabinoid Receptor Agonists
  • Cannabis* / adverse effects
  • Hallucinogens*
  • Humans
  • Male

Substances

  • Hallucinogens
  • Cannabinoid Receptor Agonists
  • Analgesics

Grants and funding

The authors received no specific funding for this work.